open access

Vol 49, No 4 (2011)
Original paper
Submitted: 2012-01-16
Published online: 2012-01-16
Get Citation

The levels of sMUC-1 in patients with multiple myeloma

Dorota Lemancewicz, Lukasz Bolkun, Halina Porowska, Marzenna Galar, Janusz Semeniuk, Janusz Kloczko, Janusz Dziecioł
DOI: 10.5603/FHC.2011.0089
·
Folia Histochem Cytobiol 2011;49(4):654-658.

open access

Vol 49, No 4 (2011)
ORIGINAL PAPERS
Submitted: 2012-01-16
Published online: 2012-01-16

Abstract

Mucins have been shown to be aberrantly overexpressed in various diseases including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the roles of these mucins in the pathogenesis of cancer. The presence of MUC-1 has also been detected on the cell surface of multiple myeloma (MM) cells in peripheral blood and showed direct correlation with tumor mass. In this study, we evaluated the levels of soluble MUC-1 (sMUC-1) in 50 new MM patients and correlated this with the levels of sMUC-1 after treatment. High levels of sMUC-1 were found in 20/50 (40%) MM patients, and in 2/50 (4%) healthy individuals (p = 0.001). According to the ISS, we found significant differences of mean sMUC-1 levels between the first stage of the disease (0.63 ± ± 0.26) and the third (0.93 ± 0.24; p = 0.03), but not with the second stage (0.80 ± 0.22; p = 0.08). Our study confirmed the correlation between elevated sMUC-1 and high elevated lactate dehydrogenase (p = 0.03) and the level of IgG in groups of patients with MM IgG at every stage of disease (p = 0.001). We showed for the first time that levels of sMUC-1 after treatment, in a group of patients with initially elevated levels of MUC-1, were statistically lower than in a group of patients with initially lower levels of sMUC-1 (21% vs. 42,6%; p = 0.05). At 37 months median of follow-up, we found a statistically significant difference between patients with normal versus elevated sMUC-1 in terms of progression-free survival (median 12 months vs. 8.1 months; p = 0.03). (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 654–658)

Abstract

Mucins have been shown to be aberrantly overexpressed in various diseases including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the roles of these mucins in the pathogenesis of cancer. The presence of MUC-1 has also been detected on the cell surface of multiple myeloma (MM) cells in peripheral blood and showed direct correlation with tumor mass. In this study, we evaluated the levels of soluble MUC-1 (sMUC-1) in 50 new MM patients and correlated this with the levels of sMUC-1 after treatment. High levels of sMUC-1 were found in 20/50 (40%) MM patients, and in 2/50 (4%) healthy individuals (p = 0.001). According to the ISS, we found significant differences of mean sMUC-1 levels between the first stage of the disease (0.63 ± ± 0.26) and the third (0.93 ± 0.24; p = 0.03), but not with the second stage (0.80 ± 0.22; p = 0.08). Our study confirmed the correlation between elevated sMUC-1 and high elevated lactate dehydrogenase (p = 0.03) and the level of IgG in groups of patients with MM IgG at every stage of disease (p = 0.001). We showed for the first time that levels of sMUC-1 after treatment, in a group of patients with initially elevated levels of MUC-1, were statistically lower than in a group of patients with initially lower levels of sMUC-1 (21% vs. 42,6%; p = 0.05). At 37 months median of follow-up, we found a statistically significant difference between patients with normal versus elevated sMUC-1 in terms of progression-free survival (median 12 months vs. 8.1 months; p = 0.03). (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 654–658)
Get Citation

Keywords

multiple myeloma; sMUC-1

About this article
Title

The levels of sMUC-1 in patients with multiple myeloma

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 4 (2011)

Article type

Original paper

Pages

654-658

Published online

2012-01-16

DOI

10.5603/FHC.2011.0089

Bibliographic record

Folia Histochem Cytobiol 2011;49(4):654-658.

Keywords

multiple myeloma
sMUC-1

Authors

Dorota Lemancewicz
Lukasz Bolkun
Halina Porowska
Marzenna Galar
Janusz Semeniuk
Janusz Kloczko
Janusz Dziecioł

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl